A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 17, 2017

Study Completion Date

May 17, 2017

Conditions
Acute Anemia
Interventions
DRUG

SANGUINATE™

As needed (PRN) infusions of 500 mL of SANGUINATE

Trial Locations (32)

10029

Mt. Sinai /Recanati/Miller Transplantation Institute, Icahn, New York

11042

Northwell - North Shore University Hospital, Lake Success

15213

University of Pittsburgh, Pittsburgh

19001

Abington University, Abington

19106

Hahnemann University Hospital (Rittenhouse), Philadelphia

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

20007

Medstar Georgetown University Hosiptal, Washington D.C.

21287

Johns Hopkins University, Baltimore

23298

Virginia Commonwealth University, Richmond

28204

Presbyterian Hospital Novant Health, Charlotte

29425

Medical University of South Carolina, Charleston

29607

Bon Secour St Francis Cancer Center, Greenville

30066

Wellstar Atlanta Medical Centre, Marietta

30912

Augusta University, Augusta

33606

Tampa General Hospital, Tampa

35213

Brookwood Princeton Baptist, Birmingham

48201

Detroit Medical Center Harper Univesity Hospital, Detroit

53214

Blood Center of Wisconsin, Milwaukee

77030

Houston Methodist Hospital, Houston

St. Lukes, Houston

79905

University of Texas Medical Center (El Paso), El Paso

86301

Yavapai Regional Medical Center, Prescott

91010

City of Hope, Duarte

91345

Providence Holy Cross Hospital, Mission Hills

91706

Kaiser Permanente, Baldwin Park

92354

Loma Linda Medical Center, Loma Linda

93534

Antelope Valley Hospital, Lancaster

98122

Swedish Medical Center, Seattle

07631

Englewood Medical Center, Englewood

07601

Hackensack University Medical Center, Hackensack

07039

St. Barnabas, Livingston

Sponsors
All Listed Sponsors
lead

Prolong Pharmaceuticals

INDUSTRY